ABC008 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 15 | Inclusion body myositis | 1 |
15. Inclusion body myositis
Clinical trials : 42 / Drugs : 60 - (DrugBank : 16) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04659031 (ClinicalTrials.gov) | May 25, 2021 | 25/11/2020 | A Phase 1 Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM) | A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM) | Inclusion Body Myositis | Drug: ABC008 | Abcuro, Inc. | NULL | Recruiting | 40 Years | N/A | All | 27 | Phase 1 | Australia |